Valine

Valine

SCHEMBL1042372

CC(C)C(N)C(=O)O.CC(C)[C@H](N)C(=O)O.N

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.94
SLC1A3 P43003 2/20 0.46
SLC1A2 P43004 2/20 0.46
SLC1A1 P43005 2/20 0.46
TP53 P04637 1/20 0.42
DPP4 P27487 1/20 0.39
FAP Q12884 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
LAP3 P28838 1/20 0.39
USP2 O75604 1/20 0.37
SLCO1B1 Q9Y6L6 1/20 0.37
GABRP O00591 4/20 0.36
GABRD O14764 4/20 0.36
GABRA1 P14867 4/20 0.36
GABRB1 P18505 4/20 0.36
GABRG2 P18507 4/20 0.36
GABRB3 P28472 4/20 0.36
GABRA5 P31644 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL4078935 1.00
Valine SCHEMBL628974 1.00 SLC7A5 (0.94) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL135483 1.00
Valine SCHEMBL6396547 0.97 SLC7A5 (0.88) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL288203 0.97 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL1813972 0.97 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL2785563 0.97 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL8516 0.97
Valine SCHEMBL41225 0.97 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL8515 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3159008-B1 USE OF ADCC-OPTIMISED ANTIBODIES FOR TREATING WEAK-RESPONSE PATIENTS LAB FRANCAIS DU FRACTIONNEMENT (FR) 2020-07-22 EP disclosed
EP-3159008-A1 USE OF ADCC-OPTIMISED ANTIBODIES FOR TREATING WEAK-RESPONSE PATIENTS Laboratoire Français du Fractionnement et des Biotechnologies (FR) 2017-04-26 EP disclosed
EP-2275134-B1 USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) 2017-02-15 EP disclosed
EP-1648513-B1 USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING PATIENTS ANSWERING WEAKLY TO ANTIBODY TREATMENT. FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES LAB (FR) 2014-09-24 EP disclosed
EP-2275134-A2 Use of ADCC-optimized antibodies for treating weak patients LFB Biotechnologies (FR) 2011-01-19 EP disclosed